All In Biotech

Drug Trial Radar · NCT07129993

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Sep 26, 2025

Primary completion

Jun 1, 2029

Study completion Jan 22, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.

Conditions

  • Urothelial Cancer
  • Bladder Cancer

Interventions

  • Dato-DXdDrug

    Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B

  • CarboplatinDrug

    Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL

  • CisplatinDrug

    Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m\^2 (Phase 2) or 70 mg/m\^2 on Day 1 or 35 mg/m\^2 on Day 1 and Day 8 each 21- day cycle (Phase 3)

  • GemcitabineDrug

    Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m\^2 on Day 1 and 8 of every 3 week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate - Part A (Phase 2)Time frame: From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months
  2. Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months
  3. Overall Survival - Part B (Phase 3)Time frame: From Phase 3 randomization to death due to any cause, up to approximately 38 months

Locations

100 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Fullerton, California · Active not recruiting

  • Research Site

    Glendale, California · Active not recruiting

  • Research Site

    La Jolla, California · Active not recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Orange, California · Active not recruiting

  • Research Site

    San Francisco, California · Active not recruiting

  • Research Site

    Aurora, Colorado · Active not recruiting

  • Research Site

    Orange City, Florida · Active not recruiting

  • Research Site

    St. Petersburg, Florida · Active not recruiting

  • Research Site

    Tamarac, Florida · Active not recruiting

  • Research Site

    Atlanta, Georgia · Active not recruiting

  • Research Site

    Locust Grove, Georgia · Active not recruiting

  • Research Site

    Effingham, Illinois · Active not recruiting

  • Research Site

    Niles, Illinois · Recruiting

  • Research Site

    Peoria, Illinois · Recruiting

  • Research Site

    Largo, Maryland · Active not recruiting

  • Research Site

    Boston, Massachusetts · Active not recruiting

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    Rochester, Minnesota · Active not recruiting

  • Research Site

    St Louis, Missouri · Active not recruiting

  • Research Site

    New York, New York · Active not recruiting

  • Research Site

    Chapel Hill, North Carolina · Recruiting

  • Research Site

    Raleigh, North Carolina · Active not recruiting

  • Research Site

    Portland, Oregon · Active not recruiting

  • Research Site

    Monroeville, Pennsylvania · Active not recruiting

  • Research Site

    Philadelphia, Pennsylvania · Active not recruiting

  • Research Site

    Providence, Rhode Island · Active not recruiting

  • Research Site

    Myrtle Beach, South Carolina · Active not recruiting

  • Research Site

    Germantown, Tennessee · Active not recruiting

  • Research Site

    Memphis, Tennessee · Active not recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Austin, Texas · Active not recruiting

  • Research Site

    Dallas, Texas · Recruiting

  • Research Site

    Dallas, Texas · Active not recruiting

  • Research Site

    Charlottesville, Virginia · Active not recruiting

  • Research Site

    Norfolk, Virginia · Recruiting

  • Research Site

    Spokane, Washington · Active not recruiting

  • Research Site

    Madison, Wisconsin · Active not recruiting

  • Research Site

    Graz, Austria · Active not recruiting

  • Research Site

    Krems, Austria · Active not recruiting

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.